Politics

On the same day South Africa was disinvited from the G7 summit under US pressure, China pledged tariff-free trade. What does this moment reveal about the battle for the Global South?

Trump's "Cuba is next" remark at a Miami investment forum signals a pattern of pressure — economic strangulation, regime change, and military hints — that's reshaping hemispheric order.

India officially declared neutrality in the Middle East conflict, but its behavior tells a different story — and may signal a quiet but profound shift in Indian grand strategy.

A top Chinese economist claims Beijing can absorb shocks from the Middle East conflict and hit its growth target — while quietly preparing for Washington to walk back trade deals.

As the US-Israel conflict with Iran disrupts Qatar's helium supply, prices have doubled and hospitals fear MRI shortages. Here's why helium is uniquely hard to replace.

BTS dropped 'Keep Swimming,' a nine-track remix album of 'Swim' reinterpreted by each member. From Afrobeats to lo-fi acoustic, it's more than music — it's a statement.

The world is watching for a Xi-Trump summit date. But the deeper question isn't when they'll meet — it's what kind of world they're building together, and apart.

Britain rejected a £1.5 billion Chinese wind turbine plant in Scotland. The reason given was national security—but the real pressure may have come from Washington.

Trump's planned May 14-15 visit to Beijing may be more than diplomacy — Chinese analysts say it could shape the US exit strategy from its war with Iran, and Beijing knows it holds the cards.

The US says talks with Iran are ongoing. Iran says there are no talks. Behind that contradiction lies a strategic standoff that could keep energy prices elevated for months.

Harvard economist Kenneth Rogoff warns the US dollar's dominance is eroding—not with a bang, but a slow bleed. What does a post-dollar world actually look like?

Semaglutide's patent expired in China on March 20. Now at least 10 Chinese rivals are queuing for approval, some claiming better efficacy. A $14B market is up for grabs.